A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
Clinical trial NCT05297890 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05297890
- Sponsor
- CStone Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-27
- Primary completion
- 2023-12-26
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.